Rekvina Laboratories is making a mandatory open offer to public shareholders at ₹10 per share, following its agreement to acquire Radiant Parenterals. This move aims to provide an exit opportunity for investors.
Rekvina Laboratories Announces Open Offer Post Acquisition
Rekvina Laboratories is set to launch a mandatory open offer for 28.90 lakh shares at ₹10 per share, with a total maximum consideration of ₹2.89 crore. This corporate action is triggered by the company's agreement to acquire 100% of Radiant Parenterals Limited via a Securities Exchange and Purchase Agreement (SEPA).
What just happened
The company will issue 46,27,750 equity shares of Rekvina at ₹10 each and 4,60,000 equity shares for cash to non-promoters as part of the acquisition consideration. Post-transaction, Dhruvalkumar Patel will join existing promoters Surbhit Mukesh Shah and Amit Mukesh Shah, reclassifying as a promoter. The total expanded capital post-transaction will be 1,11,15,750 shares.
Why this matters
This open offer, mandated by SEBI regulations, provides an exit opportunity for public shareholders at ₹10 per share. Investors need to decide whether to tender their shares, considering the company's recent return to trading and strategic business integration.
The backstory
Rekvina Laboratories has recently resumed trading and started generating revenue. The company reported ₹1.27 crore in revenue from operations for FY2026, with a net loss of ₹0.25 crore. This acquisition marks a significant step in its business development strategy.
What changes now
Upon completion of the acquisition and the open offer, Rekvina Laboratories will become the wholly-owned parent of Radiant Parenterals. Dhruvalkumar Patel's reclassification will also alter the promoter group structure.
Risks to watch
Shareholders participating in the open offer should be aware of the liquidity lock-in. Shares tendered for the offer cannot be traded or withdrawn until the entire process is concluded. The company is also operating at a loss currently, which is a key factor for investors to consider.
Peer comparison
Information on specific peers and their current financial performance or corporate actions is not detailed in the filing.
Context metrics (time-bound)
- Offer Size: 28.90 Lakh Shares
- Offer Price: ₹10 per share
- Tendering Period: July 1, 2026, to July 14, 2026
- Max Consideration: ₹2.89 Crore
- FY2026 Revenue: ₹1.27 Crore
- FY2026 Profit/(Loss): (₹0.25 Crore)
What to track next
Investors should monitor the tendering period, the outcome of the open offer, and the subsequent performance of the integrated entity. The company's ability to turn profitable post-acquisition will be crucial.
Reader Takeaway: Exit opportunity at ₹10 per share; company operates at a loss, faces liquidity lock-in.